Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varlilumab + Sunitinib in Metastatic Clear Cell Renal Cell Carcinoma
NCT02386111Phase 1Terminated
- Sponsor
- Celldex Therapeutics
- Start
- May 2015
- Primary completion
- Aug 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of varlilumab in clear cell renal cell carcinoma (ccRCC), sponsored by Celldex Therapeutics. Primary endpoint: Incidence of drug related adverse events at 100 days. Started May 2015; status: terminated.
02
Drugs
varlilumab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02386111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386111.